Department of Orthopaedic Surgery, Seoul St. Mary's Hospital, The Catholic University of Korea, Seoul, South Korea.
J Arthroplasty. 2013 Dec;28(10):1862-7. doi: 10.1016/j.arth.2013.04.020. Epub 2013 May 14.
The purpose of this study was to investigate the efficacy and safety of enoxaparin in preventing venous and arterial thromboembolism related events after primary total knee arthroplasty (TKA) in Asian patients. Four hundred twenty nine patients (621 TKAs) did not receive thromboprophylaxis after TKA and 907 patients (1,336 TKAs) received enoxaparin after the procedure. We assessed clinically significant venous and arterial thromboembolism related events and bleeding complications. Total thromboembolism related events occurred in 13 patients (3.03%) without thromboprophylaxis and 17 patients (1.87%) with enoxaparin (P = 0.183). Our study showed that the incidence of clinically significant thromboembolism related events after TKA was very low in Asian patients. Enoxaparin had no benefits in reducing thromboembolism related events in Asian patients.
本研究旨在探讨依诺肝素在预防亚洲患者初次全膝关节置换术后静脉和动脉血栓栓塞相关事件中的疗效和安全性。429 例（621 例 TKA）患者在 TKA 后未接受血栓预防治疗，907 例（1336 例 TKA）患者在术后接受了依诺肝素治疗。我们评估了临床显著的静脉和动脉血栓栓塞相关事件和出血并发症。未接受血栓预防治疗的患者中有 13 例（3.03%）和接受依诺肝素治疗的患者中有 17 例（1.87%）发生了总血栓栓塞相关事件（P = 0.183）。我们的研究表明，亚洲患者 TKA 后临床显著血栓栓塞相关事件的发生率非常低。依诺肝素在降低亚洲患者血栓栓塞相关事件方面没有益处。
Zotero 插件